Source MS Trust: A letter signed by the MS Society, MS Trust, Shift MS and leading neurologists calls on NICE, NHS England and drug manufacturer Roche to make ocrelizumab available for people with primary progressive MS.
Back in September, NICE announced that it would not be recommending ocrelizumab as an NHS treatment for early primary progressive MS. This decision was met with anger and dismay from people with MS and MS charities, and the MS Society started a petition, calling for...